Cancer cells as a new source of induced pluripotent stem cells

Abstract

Over the last 2 decades, induced pluripotent stem cells (iPSCs) have had various potential applications in various medical research areas, from personalized medicine to disease treatment. Different cellular resources are accessible for iPSC generation, such as keratinocytes, skin fibroblasts, and blood or urine cells. However, all these sources are somatic cells, and we must make several changes in a somatic cell’s transcriptome and chromatin state to become a pluripotent cell. It has recently been revealed that cancer cells can be a new source of iPSCs production. Cancer cells show similarities with iPSCs in self-renewal capacity, reprogramming potency, and signaling pathways. Although genetic abnormalities and potential tumor formation in cancer cells pose a severe risk, reprogrammed cancer-induced pluripotent stem cells (cancer-iPSCs) indicate that pluripotency can transiently overcome the cancer phenotype. This review discusses whether cancer cells can be a preferable source to generate iPSCs.

Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T‐ALL‐iPSC in vivo

“…iPSCs derived from tumor cells (such as gastrointestinal cancer cells, melanoma cells, and pancreatic ductal adenocarcinoma cells) have been widely used in cancer models and signaling pathways research [22,23]. Studies have shown that iPSCs derived from acute myeloid leukemia (AML) patient samples (AML-iPSCs) reset leukemic DNA methylation and gene expression patterns, but retain leukemic mutations [24,25].…”